SynthesisInternational ophthalmology2025
Efficacy of intravitreal injection of anti-vascular endothelial growth factor as an adjunctive treatment for proliferative diabetic retinopathy before pars plana vitrectomy: a systematic evaluation and meta-analysis.
Synthesis in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of different anti-VEGF agents combined with pars plana vitrectomy in proliferative diabetic retinopathy: a systematic review and network meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2026Pooled it
- Surgical outcomes of familial exudative vitreoretinopathy-associated retinal detachment: a systematic review and meta-analysis.International journal of retina and vitreous · 2026Review
- Clinical efficacy of Conbercept combined with pars plana vitrectomy for proliferative diabetic retinopathy.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo appraise the efficacy of anti-vascular endothelial growth factor (anti-VEGF) drugs as an adjunctive treatment before pars plana vitrectomy (PPV) in patients suffering from proliferative diabetic retinopathy (PDR).
methodsRelevant studies published up to December 2024 were retrieved from PubMed, Embase, Cochrane, and Web of Science. Data analysis was implemented by means of Stata version 15.0. Weighted mean difference (WMD), risk ratio (RR), and their corresponding 95% confidence intervals (CIs) were estimated.
results17 randomized controlled trials (RCTs) were incorporated. The meta-analysis revealed that preoperative anti-VEGF treatment in PDR patients can reduce intraoperative vitreous hemorrhage (VH) (RR = 0.38, 95% CI 0.28, 0.52, P < 0.01), decrease the incidence of iatrogenic retinal tears (RR = 0.56, 95% CI 0.43, 0.72, P < 0.01), and shorten surgical duration (WMD = - 24.04, 95% CI - 30.37, - 17.71, P < 0.01). Additionally, this treatment improves postoperative best-corrected visual acuity (BCVA) (WMD = - 0.18, 95% CI - 0.28, - 0.09, P < 0.01), reduces both early (RR = 0.63, 95% CI 0.45, 0.89, P = 0.009) and late-stage (RR = 0.43, 95% CI 0.26, 0.70, P = 0.001) VH, and accelerates the absorption of recurrent VH.
conclusionsThe preoperative use of anti-VEGF agents in PPV can reduce the incidence of intraoperative VH and retinal tears, thereby facilitating a quicker and easier surgical procedure.
Indexed as
Identifiers
41148385What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.